ATXS
Astria Therapeutics, Inc.
$12.58
+0.00
(+0.00%)
Mkt Cap
718.13M
Volume
3,057,633
52W Range
3.555-13.29
Sector
Healthcare
Beta
0.02
EPS (TTM)
-2.15
P/E Ratio
-5.33
Revenue (TTM)
706,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500,000 | 0 | 0 | 0 | 0 |
| Net Income | (94.26M) | (72.89M) | (51.83M) | (194.91M) | (37.30M) | (26.29M) | (25.87M) | (27.36M) | (36.06M) | (32.63M) | (21.88M) | (18.12M) |
| EPS | -1.68 | -2.42 | -3.55 | -24.58 | -12.20 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 |
| Free Cash Flow | (81.54M) | (68.47M) | (43.62M) | (30.17M) | (32.52M) | (26.58M) | (23.45M) | (26.89M) | (33.32M) | (30.21M) | N/A | N/A |
| FCF / Share | -1.45 | -2.27 | -2.98 | -3.38 | -10.63 | -14.24 | -27.83 | -74.42 | -123.17 | -225.42 | N/A | N/A |
| Operating CF | (81.21M) | (68.44M) | (43.53M) | (30.15M) | (32.48M) | (26.57M) | (23.46M) | (26.84M) | (32.86M) | (29.79M) | N/A | N/A |
| Total Assets | 342.36M | 254.67M | 230.63M | 127.51M | 47.46M | 41.78M | 39.17M | 17.90M | 40.21M | 64.22M | N/A | N/A |
| Total Debt | 5.35M | 329,000 | 939,000 | 365,000 | 1.05M | 2.25M | 0 | 2.48M | 5.72M | 8.95M | N/A | N/A |
| Cash & Equiv | 59.82M | 175.53M | 20.52M | 86.51M | 24.93M | 9.90M | 15.29M | 16.37M | 23.60M | 62.78M | N/A | N/A |
| Book Value | 319.26M | 243.12M | 221.22M | 122.31M | 40.67M | 35.72M | 34.94M | 11.79M | 29.09M | 50.49M | N/A | N/A |
| Return on Equity | -0.30 | -0.30 | -0.23 | -1.59 | -0.92 | -0.74 | -0.74 | -2.32 | -1.24 | -0.65 | N/A | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 706,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (31.64M) | (33.05M) | (33.71M) | (25.63M) | (24.53M) | (24.17M) | (19.93M) | (31.41M) | (17.73M) | (12.57M) | (11.19M) | (13.26M) |
| EPS | -0.55 | -0.57 | -0.58 | -0.45 | -0.43 | -0.43 | -0.38 | -0.86 | -0.63 | -0.45 | -0.40 | -0.66 |
| Free Cash Flow | (32.30M) | (36.65M) | (34.02M) | (17.36M) | (27.98M) | (17.10M) | (19.09M) | (30.25M) | (14.26M) | (10.70M) | (13.26M) | (10.70M) |
| FCF / Share | -0.56 | -0.63 | -0.59 | -0.31 | -0.50 | -0.30 | -0.37 | -0.83 | -0.51 | -0.38 | -0.47 | -0.58 |
| Operating CF | (32.30M) | (36.06M) | (34.02M) | (17.36M) | (27.96M) | (16.79M) | (19.09M) | (30.24M) | (14.26M) | (10.70M) | (13.25M) | (10.66M) |
| Total Assets | 271.87M | 281.92M | 310.39M | 342.36M | 361.64M | 367.99M | 378.81M | 254.67M | 193.86M | 207.05M | 218.24M | 230.63M |
| Total Debt | 4.46M | 4.77M | 5.06M | 5.35M | 5.64M | 5.79M | 168,000 | 329,000 | 488,000 | 643,000 | 794,000 | 939,000 |
| Cash & Equiv | 96.28M | 76.32M | 54.38M | 59.82M | 80.90M | 87.21M | 172.01M | 175.53M | 119.81M | 133.96M | 202.30M | 20.52M |
| Book Value | 233.25M | 260.51M | 289.29M | 319.26M | 341.65M | 347.08M | 367.74M | 243.12M | 184.48M | 200.40M | 211.36M | 221.22M |
| Return on Equity | -0.14 | -0.13 | -0.12 | -0.08 | -0.07 | -0.07 | -0.05 | -0.13 | -0.10 | -0.06 | -0.05 | -0.06 |
ATXS News
